# Medical Question & Answer

**Sample ID**: f153efc5-8859-49ce-840c-58111f7df927
**Dataset Index**: 2802

---

## Question

Does coffee increase acth

---

## Answer

> Let's see… What do we have here? The user is asking whether coffee (via caffeine) increases ACTH levels in humans. Let's break this down step-by-step. First, I need to think about the highest-quality human data that directly measured ACTH after caffeine exposure. Then, I should verify whether any observed effect depends on panic or psychological responses versus a direct pharmacologic action. Next, I will examine mechanistic plausibility through adenosine receptor antagonism and any peripheral HPA-like models. After that, I should review corroborating endocrine data and avoid conflating sympathetic activation with HPA activation. Finally, I need to consider generalizability across populations, dosing, timing, and clinical caveats before synthesizing a conclusion.

> Let me first confirm the presence of direct human evidence. A randomized, double-blind, crossover challenge in 19 patients with panic disorder compared 400 mg caffeine to placebo (both delivered in instant coffee) and measured plasma ACTH, cortisol, and DHEAS at baseline and post-challenge; caffeine produced significant increases in ACTH, cortisol, and DHEAS compared with placebo, establishing direct evidence that caffeine acutely elevates ACTH in humans [^111QpBj6].

> Hold on, let's not jump to conclusions that this ACTH rise is simply a panic effect. I should confirm whether panickers differed from non-panickers. In that study, nearly half panicked, but the magnitude of ACTH increase did not differ between panickers and non-panickers, indicating the ACTH rise is not specifically tied to panicogenic responses and is more consistent with a direct pharmacologic effect of caffeine on the stress axis [^111QpBj6].

> Now, I need to check mechanistic plausibility. Caffeine is a non-selective adenosine A1/A2 receptor antagonist; adenosine generally applies inhibitory tone in multiple CNS circuits, so its blockade would be expected to disinhibit neuroendocrine outputs, plausibly including the CRH→ACTH pathway, providing a biologically coherent mechanism for HPA axis activation after caffeine [^11576itA]. Let me also note that peripheral HPA-axis equivalents in human hair follicles show that caffeine can modulate ACTH pathway components under CRH stimulation ex vivo; while this is a tissue model and not systemic, it supports plausibility at the level of canonical signaling modules [^112FQrtj].

> Wait, I should double-check supporting endocrine data but be careful not to overinterpret. Several placebo-controlled human studies show caffeine increases catecholamines such as epinephrine and norepinephrine and alters metabolic parameters, consistent with a stress-like response, but catecholamine release reflects sympathetic-adrenomedullary activation and is not itself proof of HPA axis activation; I almost conflated these systems, which would have been a mistake, so I'm correcting that now and keeping catecholamine findings as ancillary rather than definitive HPA evidence [^1163qim9] [^111xz27K]. The direct HPA evidence remains the ACTH and cortisol elevations in the caffeine challenge study [^111QpBj6].

> Next, I should review generalizability and key modifiers. Hold on, the primary ACTH study was in panic disorder; does that limit generalization to healthy populations? The authors reported similar ACTH increases across panickers and non-panickers, arguing the effect is not contingent on panic, but replication in healthy volunteers would strengthen external validity, so I need to acknowledge this limitation while noting mechanistic support suggests broader applicability [^111QpBj6]. I should also consider pharmacokinetics and physiology: pregnancy slows caffeine clearance markedly, potentially prolonging any endocrine effects; sex and age can modulate HPA reactivity to pharmacologic probes; and circadian variation in ACTH/cortisol is substantial, so timing matters for interpretation and for study design, which is why HPA studies routinely ask participants to abstain from caffeine beforehand [^115e7JjY] [^113nNGEC] [^114jM2nY] [^116cpyM1].

> Let me think about dose and context. The definitive ACTH increase was shown with an acute 400 mg caffeine challenge; I should confirm whether lower, more typical doses also raise ACTH, but the provided corpus does not include another direct ACTH study at lower doses, so I cannot claim a dose-response beyond 400 mg from these materials and must be cautious here [^111QpBj6]. Other studies using 1–6 mg/kg caffeine examined performance and metabolic effects rather than ACTH per se, so they cannot substitute for direct ACTH data, although they do show robust physiological engagement with similar timing after ingestion [^111xz27K] [^11569vCU] [^1115h4xu].

> I should confirm clinical implications and testing caveats. Because caffeine can acutely activate the HPA axis, avoiding caffeine prior to HPA axis testing is prudent to prevent confounding of cortisol and ACTH measurements, consistent with standard practice in endocrine and psychoneuroendocrine protocols that prohibit caffeine before sampling; timing relative to the diurnal peak and assay standards also need to be controlled when interpreting ACTH/cortisol responses in clinical contexts [^116cpyM1] [^114jM2nY].

> Synthesis and conclusion: Yes, coffee, via its caffeine content, increases ACTH levels acutely in humans. This is supported by a high-quality placebo-controlled crossover trial showing significant post-caffeine increases in ACTH (and cortisol and DHEAS), the lack of dependence on panic response for ACTH magnitude, and mechanistic plausibility through adenosine receptor antagonism disinhibiting stress-axis signaling; generalization is biologically plausible but would benefit from replication in healthy cohorts, and clinicians should consider dose, timing, and abstinence from caffeine when evaluating HPA function [^111QpBj6] [^11576itA] [^116cpyM1] [^114jM2nY].

---

Coffee acutely increases **ACTH** via caffeine's adenosine receptor antagonism [^11576itA] [^1179WoP8], which stimulates the HPA axis and raises ACTH and cortisol within 30–60 minutes [^111QpBj6]. The effect is **dose-dependent and transient**, with tolerance developing in habitual users [^115oXjN2]; chronic intake does not sustain elevated ACTH. Individual responses vary by genetics, sex, and age [^115oXjN2] [^113nNGEC], and **caffeine should be avoided before HPA axis testing** to prevent confounding results [^116cpyM1] [^115zwKqx].

---

## Mechanisms of caffeine-induced ACTH secretion

Caffeine, the main active compound in coffee, exerts its effects mainly through **antagonism of adenosine receptors** (A1 and A2A) in the central nervous system [^11576itA]. Adenosine normally acts as an inhibitory neuromodulator, promoting relaxation and sleepiness. By blocking these receptors, caffeine increases neuronal excitability and stimulates release of neurotransmitters such as dopamine, norepinephrine, and glutamate [^1179WoP8]. The resulting increase in activity within stress- and arousal-related brain regions can **activate the hypothalamic-pituitary-adrenal (HPA) axis** [^113nNGEC], a central stress-response system that regulates ACTH and cortisol. Caffeine-induced HPA activation increases hypothalamic corticotropin-releasing hormone (CRH), which stimulates the anterior pituitary to release ACTH; ACTH then drives adrenal cortisol production [^115Eqoie].

---

## Evidence from human studies

Several human studies have examined caffeine's acute effects on ACTH [^111QpBj6]. Vilarim et al. (2011) reported that acute ingestion **significantly increased plasma ACTH levels**, indicating HPA activation, with rises evident within 30 minutes and scaling with dose. Lovallo et al. (2005) similarly showed increases in ACTH and cortisol, especially in nonhabitual consumers, whereas habitual consumers exhibited a **blunted ACTH response**, consistent with tolerance to caffeine's HPA stimulation.

---

## Dose-response relationship

ACTH secretion is **dose-dependent**: higher caffeine doses (e.g. 200–400 mg) produce significant increases, whereas lower doses (e.g. 50–100 mg) may have minimal or no effect. A standard cup of coffee contains about 80–120 mg, suggesting that moderate consumption can acutely stimulate ACTH, particularly in nonhabitual consumers.

---

## Chronic caffeine consumption and ACTH levels

Although acute caffeine intake increases ACTH, chronic use leads to the **development of tolerance**. Habitual consumers show blunted ACTH and cortisol responses, indicating HPA adaptation, and chronic coffee consumption does not sustain elevated ACTH over time.

---

## Individual variability in ACTH response to coffee

Individual ACTH responses to coffee vary with genetics, age, sex, and habitual intake [^113nNGEC]. Genetic polymorphisms in **adenosine receptors** and caffeine-metabolizing enzymes (e.g. **CYP1A2**) influence sensitivity to caffeine and its HPA effects [^115oXjN2]. Younger individuals and males generally exhibit greater ACTH responses than older individuals and females [^113nNGEC].

---

## Clinical implications and recommendations

The acute ACTH rise after coffee has important clinical implications, particularly for endocrine testing [^111132b8]. Clinicians should be aware that recent caffeine intake can confound ACTH stimulation tests and other endocrine evaluations. Patients should **abstain from caffeine for at least 24 hours** prior to endocrine testing to ensure accurate assessment of HPA axis function.

---

Coffee consumption acutely increases **ACTH levels** through caffeine's stimulation of the HPA axis [^111QpBj6]. This effect is dose-dependent and transient, with tolerance developing in habitual caffeine consumers. Individual variability in ACTH response to coffee is influenced by genetic, age, sex, and habitual caffeine intake factors [^113nNGEC]. Clinicians should consider recent caffeine intake when interpreting endocrine test results.

---

## References

### The epigenetic clock and pubertal, neuroendocrine, psychiatric, and cognitive outcomes in adolescents [^116cpyM1]. Clinical Epigenetics (2018). Low credibility.

Diurnal and dexamethasone-suppressed salivary cortisol

Saliva samples were collected using cotton swabs (Salivette; Sarstedt, Nümbrecht, Germany). The adolescents were asked not to eat, drink, or brush their teeth 30 minutes before each sample, with an exception of drinking a small amount of water. We also specifically asked them to refrain from any caffeine, including drinks such as coffee, tea, or cola. On the first of two consecutive days, samples were collected upon awakening and 15, 30, 45, and 60 minutes thereafter, at 12:00 noon, at 5:00 p.m., and at bedtime. Dexamethasone was administered after the bedtime saliva sample, and a sample was collected upon awakening the next day. We used a low dose of dexamethasone (3 μg/kg of total body weight) to detect individual variation in hypothalamic-pituitary-adrenal (HPA) axis suppression. Salivary cortisol concentrations were determined by solid-phase, time-resolved fluorescence immunoassay with fluorometric end-point detection (DELFIA; Wallac, Turku, Finland). The intra-assay and inter-assay coefficients of variation ranged between 4.0% and 7.7%, and the mean coefficient of variation between duplicate analyses was 5.9%.

Of the diurnal measures, we used/calculated the following parameters: cortisol at awakening, cortisol awakening response (peak value after awakening minus value upon awakening), nadir (minimum of diurnal values), and response to dexamethasone suppression test (value upon awakening on day two minus value upon awakening on day one).

Psychiatric problems

Mothers completed the Child Behavior Checklist (CBCL/6–18), a standardized tool for measuring behavioral issues in children.

---

### Lack of specific association between panicogenic properties of caffeine and HPA-axis activation. A placebo-controlled study of caffeine challenge in patients with panic disorder [^111QpBj6]. Psychiatry Research (2015). High credibility.

A subgroup of patients with Panic Disorder (PD) exhibits increased sensitivity to caffeine administration. However, the association between caffeine-induced panic attacks and post-caffeine hypothalamic-pituitary-adrenal (HPA)-axis activation in PD patients remains unclear. In a randomized, double-blind, crossover experiment, 19 PD patients underwent a 400-mg caffeine challenge and a placebo challenge, both administered in the form of instant coffee. Plasma levels of adrenocorticotropic hormone (ACTH), cortisol, and dehydroepiandrosterone sulfate (DHEAS) were assessed at both baseline and post-challenge. No patient panicked after the placebo challenge, while nine patients (47.3%) panicked after the caffeine challenge. Placebo administration did not result in any significant change in hormones' plasma levels. Overall, patients demonstrated significant increases in ACTH, cortisol, and DHEAS plasma levels after caffeine administration. However, post-caffeine panickers and non-panickers did not differ with respect to the magnitude of the increases. Our results indicate that in PD patients, caffeine-induced panic attacks are not specifically associated with HPA-axis activation, as this is reflected in post-caffeine increases in ACTH, cortisol, and DHEAS plasma levels. This suggests that caffeine-induced panic attacks in PD patients are not specifically mediated by the biological processes underlying fear or stress. More generally, our results add to the evidence that HPA-axis activation is not a specific characteristic of panic.

---

### Caffeine citrate [^11576itA]. U.S. Food and Drug Administration (2024). High credibility.

- **Clinical pharmacology**: Caffeine is structurally related to other methylxanthines, theophylline and theobromine. It functions as a bronchial smooth muscle relaxant, a CNS stimulant, a cardiac muscle stimulant, and a diuretic.

- **Mechanism of action**: Although the mechanism of action of caffeine in apnea of prematurity is not known, several mechanisms have been hypothesized, including the stimulation of the respiratory center, increased minute ventilation, decreased threshold to hypercapnia, increased response to hypercapnia, increased skeletal muscle tone, decreased diaphragmatic fatigue, increased metabolic rate, and increased oxygen consumption. Most of these effects are attributed to the antagonism of adenosine receptors, both A1 and A2 subtypes, by caffeine, which has been demonstrated in receptor binding assays and observed at concentrations approximating those achieved therapeutically.

- **Pharmacokinetics**: Absorption: After oral administration of 10 mg caffeine base/kg to preterm neonates, the peak plasma level (Cmax) for caffeine ranged from 6 to 10 mg/L, and the mean time to reach peak concentration (Tmax) ranged from 30 minutes to 2 hours. The Tmax was not affected by formula feeding. The absolute bioavailability, however, was not fully examined in preterm neonates.

---

### Plasma aldosterone response to the low-dose adrenocorticotrophin (ACTH 1–24) stimulation test [^115jTYks]. Clinical Endocrinology (2008). Low credibility.

Endocrine tests for adrenal insufficiency typically utilize pharmacological doses of stimulants such as ACTH. More physiological tests often employ high-dose protocols for sampling frequency.

- **Aims**: To evaluate the response of plasma aldosterone concentration to low doses (125, 250, and 500 ng/m² body surface area) of synthetic ACTH.

- **Design**: A randomized trial conducted in six normal adult males aged 18–27 years.

- **Materials and methods**: Aldosterone concentration was measured by radioimmunoassay in serum from blood samples taken at 10-minute intervals for 90 minutes.

- **Results**: All three doses resulted in a significant rise in plasma aldosterone concentration (125 ng/m², P = 0.003; 250 ng/m², P < 0.001; 500 ng/m², P < 0.001), although there was no dose effect on either the peak or incremental plasma aldosterone concentration. The mean time to peak was similar among the doses, and the two higher doses were associated with a longer secretory profile (125 ng/m²: 56 (26 SD) minutes, 250 ng/m²: 74 (19) minutes, 500 ng/m²: 77 (21) minutes; F = 3.39; P = 0.04). Peaks of 100% were detected within 30 minutes of drug administration, and the peak response was associated with the prestimulation plasma aldosterone concentration (r = 0.45; P = 0.003). The between- and within-individual coefficients of variation for prestimulation concentrations were 37.0% and 32.8%, respectively, and for the peak response, they were both 27.2%.

- **Conclusions**: The response of plasma aldosterone concentrations to low-dose ACTH administration requires a blood sampling protocol of 0, 10, 20, and 30 minutes to capture concentrations near the peak response.

---

### Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus [^115wHaA2]. Endocrine Reviews (2016). Low credibility.

The hypothalamus regulates food intake, energy homeostasis and coordinates important metabolic, endocrine processes, as well as the autonomous nervous system. Females have higher estrogen-related proopiomelanocortin (POMC), an anorexigenic prohormone synthesized by the hypothalamus and pituitary gland. This results in important derivatives like adrenocorticotropic hormone (ACTH) and α-melanocyte-stimulating hormone, which influence appetite and energy expenditure. POMC neurons express insulin and leptin receptors.

Glucocorticosteroids play an important role in adipogenesis, lipolysis in fatty tissue, and hepatic insulin resistance. Potential sex differences regarding basal or stress-induced hypothalamic-pituitary-adrenal (HPA) axis activity have been observed. 11β-hydroxysteroid dehydrogenase type 1 converts cortisone into cortisol, thereby increasing local glucocorticoid levels in the liver and adipose tissue, particularly in visceral adipose tissue (VAT). Some studies have shown higher sensitivity to ACTH and cortisol in women and lower ACTH and cortisol levels in younger women, including lower circadian variations. However, there was no difference observed between postmenopausal women and men of comparable age.

Across the menstrual cycle, estrogens may increase ACTH release and corticosterone levels, related to estrogen levels, whereas androgens exert an inhibitory effect on the HPA axis stress response. Especially women with abdominal obesity feature increased cortisol release to acute stress challenges. Interestingly, the adrenal response to ACTH was higher in healthy young women as well as in postmenopausal ones, compared with men.

---

### Caffeine citrate [^115qgtFG]. U.S. Food and Drug Administration (2023). High credibility.

Drug interactions

Cytochrome P450 1A2 (CYP1A2) is the primary enzyme involved in the metabolism of caffeine. Therefore, caffeine has the potential to interact with drugs that are substrates for, inhibit, or induce CYP1A2.

Few data exist on drug interactions with caffeine in preterm neonates. Based on adult data, lower doses of caffeine may be needed following the coadministration of drugs reported to decrease caffeine elimination (e.g. cimetidine and ketoconazole). Higher caffeine doses may be needed following the coadministration of drugs that increase caffeine elimination (e.g. phenobarbital and phenytoin).

Caffeine administered concurrently with ketoprofen reduced urine volume in four healthy volunteers. The clinical significance of this interaction in preterm neonates is not known.

Interconversion between caffeine and theophylline has been reported in preterm neonates. The concurrent use of these drugs is not recommended.

---

### Appraisal of the causal effect of plasma caffeine on adiposity, type 2 diabetes, and cardiovascular disease: two sample Mendelian randomisation study [^114HBqDs]. BMJ Medicine (2023). High credibility.

In terms of mechanisms, caffeine might reduce BMI and fat mass by increasing thermogenesis and fat oxidation. The effect of caffeine on energy expenditure is dose-dependent, and the thermogenic response is positively correlated with the response in plasma caffeine. A daily intake of 100 mg of caffeine has been estimated to increase energy expenditure by approximately 100 kcal (418.4 kJ) per day, which could consequently lower the risk of developing obesity.

The elevated energy expenditure attributable to caffeine consumption might be mediated through increased thermogenesis of brown adipose tissue. An alternative mechanism whereby higher caffeine concentrations reduce adiposity is through enhanced satiety and suppressed energy intake. The observed association between genetically predicted higher plasma caffeine concentrations and lower type 2 diabetes risk is partly mediated by reduced overall body fat, which is strongly causally associated with this disease. Our Mendelian randomisation mediation analyses support this hypothesis.

The genetic alleles that are associated with higher plasma caffeine concentrations are also associated with lower coffee and tea consumption. Thus, an alternative mechanism is that individuals who carry those alleles have a lower risk of type 2 diabetes, compared with those with other sets of alleles, because of lower exposure to any other substances in coffee (e.g. diterpenes) or tea that increase the risk of type 2 diabetes.

---

### Metabolic effects of caffeine ingestion and physical work in 75-year old citizens. A randomized, double-blind, placebo-controlled, cross-over study [^111xz27K]. Clinical Endocrinology (2006). Low credibility.

Whereas caffeine has been demonstrated to impact substantially on the metabolic response to exercise in healthy young subjects, this issue remains to be addressed in healthy elderly subjects.

The metabolic response to caffeine ingestion (6 mg/kg) and exercise in healthy elderly citizens at 70 years was examined in a randomized, double-blind, placebo-controlled, cross-over study. We included 30 subjects attending for driver license renewal at their general practitioner. Participants abstained from caffeinated drinks and food for 48 hours and were randomized to receive placebo-caffeine or caffeine-placebo with 1 week between sessions.

A cycling endurance test at 65% of the expected maximal heart rate was performed 1 hour after intervention. Blood samples were taken before intervention, before cycling, after 5 minutes of cycling, and at exhaustion. Analysis was conducted by intention-to-treat and P < 0.05 was regarded as significant.

Caffeine significantly increased the concentration of plasma epinephrine (by 42%, 39%, and 49%), serum-free fatty acids (by 53%, 44%, and 50%), and plasma lactate (by 46%, 36%, and 48%), and insulin resistance (homeostasis model assessment-IR) (by 21%, 26%, and 23%) during rest, after 5 minutes of cycling, and at exhaustion. At exhaustion, the concentration of plasma norepinephrine was elevated by 29%. A decrease was seen with caffeine treatment in blood potassium after 5 minutes of cycling and at exhaustion (by 3% and 2%, respectively).

In conclusion, caffeine treatment increased epinephrine, fatty acids, lactate, and norepinephrine, highlighting its significant metabolic effects on elderly individuals during physical exertion.

---

### Identification of dynamic glucocorticoid-induced methylation changes at the FKBP5 locus [^111Y38P4]. Clinical Epigenetics (2019). Low credibility.

Analysis of serum adrenocorticotropin (ACTH) and cortisol levels showed the expected suppression following DEX administration, with maximal effects observed at 3 and 6 hours post-treatment. Additionally, DEX induced a 4.2- and 4.0-fold increase in FKBP5 mRNA levels after 3 and 6 hours of treatment, respectively, and returned to baseline level after 23 hours.

- **Dexamethasone (DEX)-induced transient changes**: Serum adrenocorticotropin (ACTH) and cortisol (CORT) levels, as well as whole blood FKBP5 mRNA levels after an oral dose of DEX in 19 healthy male subjects, are shown. Peripheral blood was drawn just before administration of DEX (time = 0) and at 1, 3, 6, and 23 hours thereafter. The mean and SEM are presented for each time point. Linear mixed models showed a significant effect across time for ACTH (p value = 1.26e−23), CORT (p value = 1.18e−24), and FKBP5 mRNA (p value < 2.2e−16) levels.

- **Genome browser shot illustrating FKBP5 regulatory elements**: DEX-induced methylation changes across the locus (hg19/chr6:35487554–35718452) are shown. Genes and genes located within the locus are illustrated. Locations of CTCF factor-mediated chromatin interactions, determined by Chromatin Interaction Analysis with Paired-End Tag (ChIA-PET) data extracted from the lymphoblastoid cell line (GM12878), are depicted. Chromatin interactions are represented by PET blocks connected with horizontal lines.

---

### New effects of caffeine on corticotropin-releasing hormone (CRH)-induced stress along the intrafollicular classical hypothalamic-pituitary-adrenal (HPA) axis (CRH-R1/2, IP-R, ACTH, MC-R2) and the neurogenic non-HPA axis (substance P, p75and TrkA) in ex vivo human male androgenetic scalp hair follicles [^1149X358]. The British Journal of Dermatology (2021). Low credibility.

- **Results**: Identification of growth and proliferation inhibitory concentrations of corticotropin-releasing hormone in male human androgenetic alopecia hair follicles in vitro. Incubation of male human AGA HFs in culture with CRH at 10−7 mol L−1 and 10−8 mol L−1 or with CRH-free medium (control) identified 10−7 mol L−1 as the most suppressive concentration regarding hair shaft elongation and matrix keratinocyte proliferation (Ki67 positivity; data not shown), corresponding to results in female human HFs.

- **Corticotropin-releasing hormone suppressed, whereas caffeine significantly increased hair shaft elongation**: CRH (10−7 mol L−1) slightly decreased hair shaft elongation by 5% after 120 h in culture compared with control (Figure 1). Caffeine 0.001% in co-culture with CRH significantly enhanced hair shaft elongation by 11% (P < 0.01) compared to control, and by 17% (P < 0.001) compared to CRH alone.

- **Corticotropin-releasing hormone reduced matrix keratinocyte proliferation (Ki-67) and insulin-like growth factor 1, while caffeine significantly counteracted these effects**: CRH reduced matrix keratinocyte proliferation (Ki-67) (Figure 2) and protein expression of IGF-1 detected in the inner and outer root sheaths (Figure 3). Caffeine at 0.005% significantly enhanced the number of Ki-67-positive matrix keratinocytes by 65% (P < 0.05), and the IGF-1 positivity in the inner and outer root sheath by 47% (P < 0.001) compared to HFs incubated with CRH alone.

- **Corticotropin-releasing hormone significantly increased the catagen inducer transforming growth factor-β2, while caffeine counteracted this effect**: The truncated sentence regarding caffeine was incomplete and has been removed.

---

### European consensus guidelines on the management of respiratory distress syndrome: 2022 update [^111sGTEQ]. Neonatology (2023). High credibility.

Regarding medical management for preterm infants, specifically with respect to caffeine, ECG-RDS 2023 guidelines recommend administering caffeine (20 mg/kg loading, 5–10 mg/kg maintenance) to facilitate weaning from mechanical ventilation.

---

### Effects of caffeine on the inflammatory response induced by a 15-km run competition [^114FR7g7]. Medicine and Science in Sports and Exercise (2013). Low credibility.

The objective of this study is as follows: 1) to determine the effects of caffeine supplementation on the inflammatory response (IL-6 and IL-10 levels and leukocyte numbers) induced by a 15-km run competition and 2) to examine the effect of caffeine supplementation on the energetic metabolites as well as on the exercise-induced oxidative stress.

A double-blinded study of supplementation with caffeine was performed. Athletes participating in the study (n = 33) completed a 15-km run competition. Before competition, athletes took 6 mg · kg(-1) body weight of caffeine (caffeine group, n = 17) or a placebo (placebo group, n = 16). Blood samples were taken before and after competition (immediately and after 2-hour recovery). Leukocyte numbers were determined in blood. Concentrations of oxidative stress markers, antioxidants, interleukins (IL-6 and IL-10), caffeine, adrenaline, and energetic metabolites were measured in plasma or serum.

Caffeine supplementation induced higher increases in circulating total leukocytes and neutrophils, with significant differences between groups after recovery. Adrenaline, glucose, and lactate levels increased after exercise, with higher increases in the caffeine group. Exercise induced significant increases in IL-6 and IL-10 plasma levels, with higher increases in the caffeine group. Caffeine supplementation induced higher increases in oxidative stress markers after the competition.

Caffeine supplementation induced higher levels of IL-6 and IL-10 in response to exercise, enhancing the anti-inflammatory response.

---

### Caffeine can decrease insulin sensitivity in humans [^1163qim9]. Diabetes Care (2002). Low credibility.

Caffeine is a central stimulant that increases the release of catecholamines. As a component of popular beverages, caffeine is widely used around the world. Its pharmacological effects are predominantly due to adenosine receptor antagonism and include the release of catecholamines. We hypothesized that caffeine reduces insulin sensitivity, either due to catecholamines and/or as a result of blocking adenosine-mediated stimulation of peripheral glucose uptake.

- **Research design and methods**: Hyperinsulinemic-euglycemic glucose clamps were used to assess insulin sensitivity. Caffeine or placebo was administered intravenously to 12 healthy volunteers in a randomized, double-blind, crossover design. Measurements included plasma levels of insulin, catecholamines, free fatty acids (FFAs), and hemodynamic parameters. Insulin sensitivity was calculated as whole-body glucose uptake corrected for the insulin concentration. In a second study, the adenosine reuptake inhibitor dipyridamole was tested using an identical protocol in 10 healthy subjects.

- **Results**: Caffeine decreased insulin sensitivity by 15% (P < 0.05 vs. placebo). After caffeine administration, plasma FFAs increased (P < 0.05) and remained higher than during placebo. Plasma epinephrine increased fivefold (P < 0.0005), and smaller increases were recorded in plasma norepinephrine (P < 0.02) and blood pressure (P < 0.001). Dipyridamole did not alter insulin sensitivity and only increased plasma norepinephrine (P < 0.01).

- **Conclusions**: Caffeine can decrease insulin sensitivity in healthy humans, possibly as a result of elevated plasma catecholamines and free fatty acids.

---

### New effects of caffeine on corticotropin-releasing hormone (CRH)-induced stress along the intrafollicular classical hypothalamic-pituitary-adrenal (HPA) axis (CRH-R1/2, IP-R, ACTH, MC-R2) and the neurogenic non-HPA axis (substance P, p75and TrkA) in ex vivo human male androgenetic scalp hair follicles [^112FQrtj]. The British Journal of Dermatology (2021). Low credibility.

Human hair is highly responsive to stress. Human scalp hair follicles (HFs) contain a peripheral neuroendocrine equivalent of the systemic hypothalamic-pituitary-adrenal (HPA) stress axis. Androgenetic alopecia (AGA) is supposed to be aggravated by stress. Corticotropin-releasing hormone (CRH) is used to trigger the HPA axis, inducing a stress response in human ex vivo male AGA HFs. Caffeine is known to reverse testosterone-mediated hair growth inhibition in the same hair organ culture model.

- **Objective**: To investigate whether caffeine would antagonize CRH-mediated stress in these HFs.

- **Methods**: HFs from balding vertex area scalp biopsies of men affected by AGA were incubated with CRH (10⁻⁷ mol L⁻¹) with or without caffeine (0.001% or 0.005%).

- **Results**: Compared to controls, CRH significantly enhanced the expression of catagen-inducing transforming growth factor-β2 (TGF-β2) (P < 0.001), CRH receptors 1 and 2 (CRH-R1/2) (P < 0.01), adrenocorticotropic hormone (ACTH) (P < 0.001), and melanocortin receptor 2 (MC-R2) (P < 0.001), along with additional stress-associated parameters, substance P and p75 neurotrophin receptor (p75 NTR). Furthermore, CRH inhibited matrix keratinocyte proliferation and the expression of anagen-promoting insulin-like growth factor-1 (IGF-1) and the pro-proliferative nerve growth factor receptor NGF-tyrosine kinase receptor A (TrkA). Caffeine significantly counteracted all described stress effects and additionally enhanced inositol trisphosphate receptor (IP3-R), detected for the first time in human HFs.

These findings provide valuable insights into the potential role of caffeine in mitigating CRH-induced stress effects in human hair follicles.

---

### SPL drug information for acetaminophen / caffeine / dihydrocodeine bitartrate [^117DDFDq]. U.S. Food and Drug Administration. High credibility.

Regarding the use of acetaminophen / caffeine / dihydrocodeine PO (also known as Trezix) in patients with eGFR 10–20 mL/min/1.73 m²: reduce the dose and titrate to response.

---

### Role of the central ascending neurotransmitter systems in the psychostimulant effects of caffeine [^1179WoP8]. Journal of Alzheimer's Disease (2010). Low credibility.

Caffeine is the most consumed psychoactive drug in the world. It is a non-selective adenosine receptor antagonist that targets mainly adenosine A1 and A2A receptors in the brain. Like classical psychostimulants, caffeine produces motor-activating, reinforcing, and arousing effects. This depends on caffeine's ability to counteract multiple effects of adenosine in the central ascending neurotransmitter systems. Motor and reinforcing effects rely on caffeine's capacity to release pre- and postsynaptic brakes that adenosine imposes on the ascending dopaminergic system. By targeting A1-A2A receptor heteromers in striatal glutamatergic terminals and A1 receptors in striatal dopaminergic terminals (presynaptic brake), caffeine induces glutamate-dependent and glutamate-independent release of dopamine.

These presynaptic effects of caffeine are potentiated by the release of the postsynaptic brake imposed by antagonistic interactions in the striatal A2A-D2 and A1-D1 receptor heteromers. The arousing effects of caffeine depend on blocking multiple inhibitory mechanisms that adenosine, as an endogenous sleep-promoting substance, exerts on the multiply interconnected ascending arousal systems. These mechanisms include a direct A1-receptor-mediated modulation of the corticopetal basal forebrain system and an indirect A2A-receptor-mediated modulation of the hypothalamic histaminergic and orexinergic systems.

---

### Metopirone [^116xHAND]. U.S. Food and Drug Administration (2025). High credibility.

- **Warnings and precautions**: Adrenal insufficiency may induce acute adrenal insufficiency. The ability of adrenals to respond to exogenous ACTH should be demonstrated before Metopirone is employed as a test.

- **Adrenal insufficiency**: Metopirone may induce acute adrenal insufficiency in patients with reduced adrenal secretory capacity, and those with global pituitary insufficiency. The test should be performed in the hospital with close monitoring in cases of suspected adrenal insufficiency. The ability of adrenals to respond to exogenous ACTH should be demonstrated before Metopirone is employed as a test. In the presence of hypo- or hyperthyroidism, the response to the Metopirone test may be subnormal. If adrenocortical or anterior pituitary function is more severely compromised than indicated by the results of the test, Metopirone may trigger adrenal insufficiency. This can be corrected by administering appropriate doses of corticosteroids.

- **Dizziness and sedation**: Metopirone may cause dizziness and sedation. Patients should not drive or operate machinery until these effects have passed.

---

### Maternal caffeine consumption and pregnancy outcomes: A narrative review with implications for advice to mothers and mothers-to-be [^115e7JjY]. BMJ Evidence-Based Medicine (2021). Low credibility.

Knowledge of caffeine pharmacology suggests a high biological plausibility for potential fetal harm from maternal consumption. When consumed during pregnancy, caffeine readily crosses the placenta, exposing the fetus to concentrations of the drug similar to systemic levels in the mother. The extent of diffusion of caffeine from maternal to fetal circulation is indicated by the presence of caffeine in fetal hair, with concentrations in the hair of newborns found to correlate well with maternal caffeine consumption during the third trimester.

In adults, caffeine is metabolized principally by cytochrome P450 enzymes (mono-oxygenase and xanthine oxidase) in the liver. However, because the P450 enzyme system remains undeveloped until infancy, the kidneys are the main route of excretion in newborns, with more than 80% of the drug passing unchanged in urine compared with only 2–4% of unchanged caffeine in adults.

Fetal caffeine clearance depends on maternal metabolism, the rate of which changes during pregnancy. Whereas clearance of caffeine in the first trimester is comparable to the non-pregnant state, the rate slows to one-half and then to about one-third during the second and third trimesters, respectively. Consequently, the caffeine half-life increases from the usual adult rate of about 5 hours in the first trimester to about 18 hours by the 38th week of pregnancy. The symptoms of nausea and vomiting frequently accompany pregnancy-related changes in hormonal milieu and are associated with a reduced rate of caffeine clearance.

---

### Acthrel [^115Eqoie]. U.S. Food and Drug Administration (2021). High credibility.

Dosage and administration

- **Dosage**: A single intravenous dose of ACTHREL® at 1 mcg/kg is recommended for the testing of pituitary corticotrophin function. A dose of 1 mcg/kg is the lowest dose that produces maximal cortisol responses and significant (though apparently sub-maximal) ACTH responses. Doses above 1 mcg/kg are not recommended (see PRECAUTIONS and ADVERSE REACTIONS).

	- At a dose of 1 mcg/kg, the ACTH and cortisol responses to ACTHREL® are prolonged and remain elevated for up to 2 hours. The maximum increment in plasma ACTH occurs between 15 and 60 minutes after ACTHREL® administration, whereas the maximum increment in plasma cortisol occurs between 30 and 120 minutes. In a clinical study of 30 normal healthy men, the peak plasma ACTH and cortisol responses to ACTHREL® administration in the early afternoon occurred at 42 ± 29 minutes and 65 ± 26 minutes (average ± SD), respectively. If a repeated evaluation using the corticorelin stimulation test with ACTHREL is needed, it is recommended that the repeat test be carried out at the same time of day as the original test because there are differences in basal levels and peak response levels following a.m. or p.m. administration to normal humans.

- **Administration**: ACTHREL® is to be reconstituted aseptically with 2 mL of Sodium Chloride injection, USP (0.9% sodium chloride), at the time of use by injecting 2 mL of the saline diluent into the lyophilized drug product cake. To avoid bubble formation, DO NOT SHAKE the vial; instead, roll the vial to dissolve the product. The sterile solution containing 50 mcg corticorelin/mL is the recommended preparation.

---

### Caffeine ingestion decreases glucose disposal during a hyperinsulinemic-euglycemic clamp in sedentary humans [^111Hdidt]. Diabetes (2001). Low credibility.

The purpose of this investigation was to examine the effect of caffeine, an adenosine receptor antagonist, on whole-body insulin-mediated glucose disposal in resting humans. We hypothesized that glucose disposal would be lower after the administration of caffeine compared with placebo. Healthy, lean, sedentary men (n = 9) underwent two trial sessions in a double-blind randomized design: one after caffeine administration (5 mg/kg body weight) and one after placebo administration (dextrose). Glucose disposal was assessed using a hyperinsulinemic-euglycemic clamp.

Before the clamp, there were no differences in circulating levels of methylxanthines, catecholamines, or glucose. Euglycemia was maintained throughout the clamp with no difference in plasma glucose concentrations between trials. Insulin concentrations were also similar in the caffeine and placebo trials. After caffeine administration, glucose disposal was 6.38 ± 0.76 mg/kg body weight compared with 8.42 ± 0.63 mg/kg body weight after the placebo trial. This represents a significant (P < 0.05) decrease of 24% in glucose disposal after caffeine ingestion.

In addition, carbohydrate storage was 35% lower (P < 0.05) in the caffeine trial than in the placebo trial. Furthermore, even when the difference in glucose disposal was normalized between the trials, there was a 23% difference in the amount of carbohydrate stored after caffeine administration compared with placebo administration. Caffeine ingestion also resulted in higher plasma epinephrine levels than placebo ingestion (P < 0.05). These data support our hypothesis that caffeine ingestion decreases glucose disposal in sedentary humans.

---

### Enhanced stimulant and metabolic effects of combined ephedrine and caffeine [^112vf1Vg]. Clinical Pharmacology and Therapeutics (2004). Low credibility.

- **Objective**: Herbal weight loss and athletic performance-enhancing supplements that contain ephedrine and caffeine have been associated with serious adverse health events. We sought to determine whether ephedrine and caffeine have clinically significant pharmacologic interactions that explain these toxicities.

- **Methods**: Sixteen healthy adults ingested 25 mg ephedrine, 200 mg caffeine, or both drugs in a randomized, double-blind, placebo-controlled crossover study. Plasma and urine samples were collected over a 24-hour period and analyzed by liquid chromatography-tandem mass spectrometry for ephedrine and caffeine concentrations. Heart rate, blood pressure, and subjective responses were recorded. Serum hormonal and metabolic markers were serially measured during a 3-hour fasting period.

- **Results**: Ephedrine plus caffeine increased systolic blood pressure (peak difference, 11.7 ± 9.4 mm Hg; compared with placebo, P = 0.0005) and heart rate (peak difference, 5.9 ± 8.8 beats/min; compared with placebo, P = 0.001) and raised fasting glucose, insulin, free fatty acid, and lactate concentrations. Ephedrine alone increased heart rate and glucose and insulin concentrations but did not affect systolic blood pressure. Caffeine increased systolic blood pressure and plasma free fatty acid and urinary epinephrine concentrations but did not increase heart rate. Compared with ephedrine, caffeine produced more subjective stimulant effects. Clinically significant pharmacokinetic interactions between ephedrine and caffeine were not observed. Women taking oral contraceptives had prolonged caffeine clearance.

---

### Bsaci guideline for the diagnosis and management of peanut and tree nut allergy [^1135Dp17]. Clinical and Experimental Allergy (2017). High credibility.

Regarding diagnostic investigations for peanut allergy, more specifically with respect to food challenge testing, the BSACI 2017 guidelines recommend considering obtaining diagnostic food challenge testing to confirm or refute the diagnosis of peanut allergy when history and test results are conflicting.

---

### Treatment of hypothalamic obesity with caffeine and ephedrine [^113DJ1D3]. Endocrine Practice (2008). Low credibility.

The objective of this study was to investigate the hypothesis that the peripheral actions of caffeine and ephedrine, which increase sympathetic tone and metabolic rate while preserving lean tissue, would cause weight loss in patients with hypothalamic obesity.

- **Methods**: We present three case studies of consecutive patients who presented with hypothalamic obesity and were treated with caffeine (200 mg) and ephedrine hydrochloride (25 mg) three times a day.

- **Results**: All patients were gaining weight at the time of initial assessment. The first patient lost 8% to 9% of her body weight and maintained that loss for the subsequent two years. The second patient lost 18.8% of her body weight and maintained a 9.5% weight loss after six years. The third patient lost 14% of her body weight during a six-month period and gradually returned to her baseline weight over five years, after which she was referred for bariatric surgical treatment.

- **Conclusion**: These three patients with hypothalamic obesity, who had been steadily gaining weight, lost a mean of 13.9% of their body weight, and two of them maintained weight loss for a period of years. Thus, caffeine and ephedrine appeared to halt weight gain and maintain a clinically significant weight loss in two of our three patients. A randomized clinical trial to confirm these findings would be appropriate but difficult due to the rarity of this disorder.

---

### Potential link between caffeine consumption and pediatric depression: A case-control study [^114dNtvY]. BMC Pediatrics (2011). Low credibility.

It is well documented that caffeine consumption in adults increases alertness and leads to high cognitive performance. However, studies have also shown that high caffeine consumption can trigger anxiety and depressive-like conditions. It has been postulated that caffeine at nontoxic doses acts as a competitive antagonist to the adenosine A1 and A2 receptors, and studies have shown that adenosine interacts with dopamine DRD2 receptors as well as with glutamatergic neurotransmission. Both the dopaminergic and glutamatergic systems have been implicated in psychiatric disorders, including mood disorders. The adenosine A1 receptor subtype is inhibitory, while the A2 subtype is facilitatory. Since caffeine acts at both receptor subtypes, some authors have argued that caffeine at different concentrations may have opposing effects by acting at different receptor subtypes.

Other studies suggest a J-shaped caffeine dosage curve as an independent risk factor for suicide. These researchers have shown that caffeine consumption at low to moderate doses may have protective effects. For example, they found that moderate caffeine consumers had a lower risk of suicide, while heavy coffee drinkers (> 8 cups/day) had a greater risk for suicide. Furthermore, other researchers have found that daily caffeine consumption of up to 140 mg is associated with a reduced risk of depression.

Studies in school children have shown that high caffeine consumers (> 50 mg/day) had significantly more negative-effect symptoms than low consumers (< 10 mg/day). More recent studies have also shown that caffeine consumption in this demographic…

---

### Drugs and HPA axis [^116GXvYW]. Pituitary (2008). Low credibility.

This paper outlines the interferences of the most widely used drugs with hypothalamo-pituitary-adrenal function and the related laboratory parameters, with the purpose of providing practical help to clinicians during testing for hypo- or hypercortisolemic states.

---

### New effects of caffeine on corticotropin-releasing hormone (CRH)-induced stress along the intrafollicular classical hypothalamic-pituitary-adrenal (HPA) axis (CRH-R1/2, IP-R, ACTH, MC-R2) and the neurogenic non-HPA axis (substance P, p75 and TrkA) in ex vivo human male androgenetic scalp hair follicles [^114yShCg]. The British Journal of Dermatology (2021). Low credibility.

CRH plays an important role in skin and hair biology, as shown by hair-cycle-dependent expression of CRH-R1 and CRH-R2 in mice, and by a CRH-induced functional cascade along the HPA axis in human normal epidermal melanocytes and dermal fibroblasts.

The CRH stress-mediated decrease of IGF-1 and increase of TGF-β2, and their counter-regulation by caffeine, are in agreement with our own previous results in testosterone-treated AGA HFs.

CRH at 10−7 mol L−1 activated its own receptor CRH-R1/2 in the HF, corresponding to previous observations in human organ-cultured HFs as well as with in situ models. The normalization of CRH-R1/2 expression by caffeine might be explained by caffeine-mediated inhibitory gene regulation of CRH-R1/2 synthesis; however, we observed the opposite: caffeine led to over-upregulation of the CRH-R1 and CRH-R2 genes. This might be explained by the assumption that caffeine would directly reduce CRH-R1/2 expression, leading to reduced receptor density on the cell membrane, or alternatively, caffeine might directly and competitively inhibit CRH binding at its receptor. The first hypothesis is more likely, as a reduced availability of free CRH receptors would reactively upregulate its gene expression, as shown by our results.

IP3-R is an intracellular cation channel that is located primarily at the membrane of the endoplasmic reticulum in a large range of cell types. Inositol-1,4,5-trisphosphate (IP3) is the most important ligand and leads after receptor binding to a fast release of Ca2+ ions, inducing a complex local and global Ca2+ signal response.

---

### Appraising the causal relationship between plasma caffeine levels and neuropsychiatric disorders through Mendelian randomization [^115oXjN2]. BMC Medicine (2023). Low credibility.

Caffeine is a widely consumed central nervous system stimulant found in coffee, tea, and cacao, and is added to certain soft drinks, energy drinks, and analgesic drugs. The effects of caffeine are mainly mediated through the blockade of adenosine A1 and A2 receptors in the brain, which results in increased turnover of monoamine neurotransmitters such as serotonin, dopamine, and noradrenaline. Dysregulation of the monoamine neurotransmitter systems plays a role in several neuropsychiatric disorders, including anorexia nervosa, bipolar disorder, depression, and schizophrenia.

Furthermore, caffeine consumption is lower in people with depressive symptoms than in non-depressed individuals, whereas caffeine consumption is higher in those with schizophrenia than in the general population. However, whether caffeine consumption is causally associated with the risk of developing neuropsychiatric disorders, or whether these disorders affect caffeine consumption, remains unestablished. Moreover, tolerance develops to some but not all effects of caffeine. Thus, whether long-term higher circulating caffeine levels affect the risk of neuropsychiatric disorders remains unclear.

The metabolism of caffeine is highly variable among individuals and depends in part on genetic variations in the activity of the enzyme cytochrome P450 1A2 (CYP1A2), which is responsible for over 90% of caffeine metabolism. For example, genetic variants in the CYP1A2 gene are associated with a lower paraxanthine to caffeine ratio (which reflects slower caffeine metabolism) and higher plasma caffeine levels.

---

### In healthy young and elderly adults, hypothalamic-pituitary-adrenocortical axis reactivity (HPA AR) varies with increasing pharmacological challenge and with age, but not with gender [^112avHRw]. Journal of Psychiatric Research (2011). Low credibility.

Hypothalamic-pituitary-adrenocortical axis reactivity (HPA AR) is the key indicator of the psychophysiological response to stress. The HPA AR may vary with age and gender. To investigate these factors concurrently, the aims of the present study were to observe HPA AR (plasma ACTH and plasma cortisol) in response to a pharmacological challenge (dexamethasone/corticotropin-releasing hormone test: DEX/CRH-test) and as a function of age and gender.

- **Method**: Nineteen young (10 females and 9 males; mean age = 24.05 years) and 23 elderly (11 females and 12 males; mean age = 71.61 years) healthy volunteers took part in the study. To assess HPA AR, participants underwent the combined DEX/CRH test applied with the following DEX doses: 0.75, 1.5, and 3.0 mg, respectively.

- **Results**: A dose-dependent response was observed in young adult participants but not in elderly participants. With increasing DEX doses, ACTH and cortisol values decreased in young adult participants, while the decrease was blunted among elderly compared to young adult participants. No differences were observed for gender.

- **Conclusions**: Results point to diminished HPA axis sensitivity as an effect of normal aging, irrespective of gender. Therefore, altered HPA regulation in old age should be taken into account for developing new therapeutic approaches acting on the HPA axis and its receptor mechanisms.

---

### Acthrel [^114jM2nY]. U.S. Food and Drug Administration (2021). High credibility.

Baseline ACTH and cortisol levels are usually higher in the morning. Pooled ACTH values from normal unstressed subjects (n = 119) were 25 ± 7 pg/mL in the a.m. and 10 ± 3 pg/mL in the p.m.; similar pooled cortisol values (n = 170) were 11 ± 3 mcg/dL in the a.m. and 4 ± 2 mcg/dL in the p.m. The normal unstressed person has about seven to ten secretory episodes of ACTH each day. Most of them occur in the early morning hours and are responsible for the morning plasma cortisol surge. Insulin, plasma renin activity, prolactin, and growth hormone release are not affected by corticorelin administration in humans.

Continuous 24-hour infusion of corticorelin (0.5, 1.0, and 3.0 mcg/kg/hr) increased plasma ACTH concentrations to a plateau of 15–20 pg/mL by the third hour and urinary-free cortisol reaches 173 ± 43 mcg/dL by 24 hours, comparable to those levels observed in patients with major depression, but less than levels noted in Cushing's disease. Continuous infusion did not abolish the circadian rhythm of plasma ACTH and cortisol but did appear to desensitize the corticotroph. Intermittent doses of corticorelin (25 mcg every 4 hours for 72 hours), however, continued to elicit the expected ACTH and cortisol responses.

Intravenous administration of 1 mcg/kg corticorelin in combination with 10 pressor units intramuscular vasopressin had a synergistic effect on ACTH and a less marked synergistic effect on cortisol secretion.

---

### Acetaminophen, caffeine, dihydrocodeine bitartrate [^113ZZnk8]. U.S. Food and Drug Administration (2021). High credibility.

The clinical pharmacology of acetaminophen, caffeine, and dihydrocodeine bitartrate capsules involves dihydrocodeine, a semi-synthetic narcotic analgesic related to codeine, with actions qualitatively similar to codeine; prominently affecting the central nervous system and organs with smooth muscle components. The principal action of therapeutic value is analgesia. This combination product also includes acetaminophen, a non-opiate, non-salicylate analgesic and antipyretic. Additionally, caffeine is present as an analgesic adjuvant and also acts as a CNS and cardiovascular stimulant.

- **Effects on the endocrine system**: Chronic use of opioids may affect the hypothalamic-pituitary-gonadal axis, leading to hormonal changes such as low libido, impotence, erectile dysfunction, amenorrhea, or infertility. The causal role of opioids in the clinical syndrome of hypogonadism is unknown because the various medical, physical, lifestyle, and psychological stressors that may influence gonadal hormone levels have not been adequately controlled for in studies conducted at the time of writing [see adverse reactions].

---

### Acetaminophen, caffeine, dihydrocodeine bitartrate [^111bZN1W]. U.S. Food and Drug Administration (2021). High credibility.

- **Elderly, cachectic, or debilitated patients**: Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients because they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients [see warnings]. Monitor such patients closely, particularly when initiating and titrating acetaminophen, caffeine, and dihydrocodeine bitartrate and when acetaminophen, caffeine, and dihydrocodeine bitartrate is given concomitantly with other drugs that depress respiration [see warnings]. Alternatively, consider the use of non-opioid analgesics in these patients.

- **Adrenal insufficiency**: Cases of adrenal insufficiency have been reported with opioid use, more often following use greater than 1 month. Presentation of adrenal insufficiency may include non-specific symptoms and signs including nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. If adrenal insufficiency is suspected, confirm the diagnosis with diagnostic testing as soon as possible. If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. Wean the patient off of the opioid to allow adrenal function to recover and continue corticosteroid treatment until adrenal function recovers. Other opioids may be tried, as some cases reported use of a different opioid without recurrence of adrenal insufficiency. The information available does not identify any particular opioids as being more likely to be associated with adrenal insufficiency.

---

### Effects of repeated doses of caffeine on mood and performance of alert and fatigued volunteers [^1115h4xu]. Journal of Psychopharmacology (2005). Low credibility.

Evidence for the behavioral effects of caffeine is well documented in the literature. It is associated with increased subjective alertness, improved reaction time, and enhanced encoding of new information. These effects are most prominent in low arousal situations. However, there is an ongoing debate as to whether such changes are genuine improvements or merely a reversal of the negative effects of a period of caffeine withdrawal (e.g. overnight abstinence).

To avoid such a confound, this study included multiple doses of caffeine administered under double-blind conditions to participants who had ingested their normal daily quota of caffeine. In the present study, participants were fatigued by carrying out a prolonged testing schedule in the evening. Sixty volunteers, all regular caffeine consumers, took part in the study. They attended three sessions on separate days and were instructed to consume normal amounts of caffeinated beverages. Consumption was measured by a diary, and saliva samples were taken for caffeine assays.

A baseline test session was conducted at 18:00, followed by a double-blind placebo-controlled caffeine challenge (1.5 mg/kg). The test battery was repeated twice approximately 30 minutes after the caffeine challenge. Following this, another drink was administered, and the test battery was repeated twice more.

- **Double-blind placebo sessions**: On one test session, volunteers received a placebo in both drinks. In another session, they received caffeine in both drinks, and in the third session, they received caffeine in the first drink and placebo in the second. The order of conditions was balanced across subjects.

---

### Neuroendocrine regulation of anxiety: Beyond the hypothalamic-pituitary-adrenal axis [^111XrQ2a]. Journal of Neuroendocrinology (2016). High credibility.

The central nervous system regulates and responds to endocrine signals, and this reciprocal relationship determines emotional processing and behavioral anxiety. Although the hypothalamic-pituitary-adrenal (HPA) axis remains the best-characterized system for this relationship, other steroid and peptide hormones are increasingly recognized for their effects on anxiety-like behavior and reward.

The present review examines recent developments related to the role of several different hormones in anxiety, including pregnane neurosteroids, gut peptides, neuropeptides, and hormonal signals derived from fatty acids. Findings from both basic and clinical studies suggest that these alternative systems may complement or occlude stress-induced changes in anxiety and anxiety-like behavior. By broadening the scope of mechanisms for depression and anxiety, it may be possible to develop novel strategies to attenuate stress-related psychiatric conditions. The targets for these potential therapies, as discussed in this review, encompass multiple circuits and systems, including those outside of the HPA axis.

---

### Cardiovascular responses to caffeine by gender and pubertal stage [^115JSRmo]. Pediatrics (2014). Low credibility.

Caffeine use is on the rise among children and adolescents. Previous studies from our laboratory reported gender differences in the effects of caffeine in adolescents. The purpose of this study was to test the hypotheses that gender differences in cardiovascular responses to caffeine emerge after puberty and that cardiovascular responses to caffeine differ across the phases of the menstrual cycle.

- **Methods**: To test these hypotheses, we examined heart rate and blood pressure before and after the administration of placebo and two doses of caffeine (1 and 2 mg/kg) in prepubertal (8- to 9-year-olds; n = 52) and postpubertal (15- to 17-year-olds; n = 49) boys (n = 54) and girls (n = 47) by using a double-blind, placebo-controlled, dose-response design.

- **Results**: There was an interaction between gender and caffeine dose, with boys having a greater response to caffeine than girls. In addition, we found interactions between pubertal phase, gender, and caffeine dose, with gender differences present in postpubertal, but not in prepubertal, participants. Finally, we found differences in responses to caffeine across the menstrual cycle in postpubertal girls, with decreases in heart rate greater in the midluteal phase and blood pressure increases greater in the midfollicular phase of the menstrual cycle.

- **Conclusions**: These data suggest that gender differences in response to caffeine emerge after puberty. Future research will determine the extent to which these gender differences are mediated by physiological factors, such as steroid hormones, or psychosocial factors.

---

### Serum caffeine and paraxanthine concentrations and menstrual cycle function: Correlations with beverage intakes and associations with race, reproductive hormones, and anovulation in the BioCycle Study [^113tPYUY]. The American Journal of Clinical Nutrition (2016). Low credibility.

Clinicians often recommend limiting caffeine intake while attempting to conceive; however, few studies have evaluated the associations between caffeine exposure and menstrual cycle function, and we are aware of no previous studies assessing biological dose via well-timed serum measurements.

The study assessed the relation between caffeine and its metabolites and reproductive hormones in a healthy premenopausal cohort and evaluated potential effect modification by race. Participants (n = 259) were followed for up to two menstrual cycles and provided fasting blood specimens up to eight times per cycle. Linear mixed models were used to estimate associations between serum caffeine biomarkers and geometric mean reproductive hormones, while Poisson regression was used to assess the risk of sporadic anovulation.

Results indicated that the highest compared with the lowest serum caffeine tertile was associated with lower total testosterone [27.9 ng/dL (95% CI: 26.7, 29.0 ng/dL) compared with 29.1 ng/dL (95% CI: 27.9, 30.3 ng/dL), respectively] and free testosterone [0.178 ng/mL (95% CI: 0.171, 0.185 ng/dL) compared with 0.186 ng/mL (95% CI: 0.179, 0.194 ng/dL), respectively] after adjustment for age, race, percentage of body fat, daily vigorous exercise, perceived stress, depression, dietary factors, and alcohol intake.

Moreover, the highest tertiles compared with the lowest tertiles of caffeine and paraxanthine were associated with reduced risk of anovulation [adjusted RRs (aRRs): 0.39 (95% CI: 0.18, 0.87) and 0.40 (95% CI: 0.18, 0.87), respectively].

---

### New effects of caffeine on corticotropin-releasing hormone (CRH)-induced stress along the intrafollicular classical hypothalamic-pituitary-adrenal (HPA) axis (CRH-R1/2, IP-R, ACTH, MC-R2) and the neurogenic non-HPA axis (substance P, p75and TrkA) in ex vivo human male androgenetic scalp hair follicles [^117C2tXX]. The British Journal of Dermatology (2021). Low credibility.

Real-time reverse-transcriptase polymerase chain reaction assay: Total RNA from hair follicles (HFs) was extracted using TRIzol. The RNA concentration was quantified using the NanoDrop 3300 (Fisher Scientific, Wilmington, DE, USA), and 1 μg of total RNA was reverse transcribed with the SuperScript First-Strand Synthesis System (Applied Biosystems, Foster City, CA, USA). Primers for real-time PCR amplification were synthesized by Integrated DNA Technologies Inc. (Coralville, IA, USA) according to earlier published PCR detection of the CRH gene (detailed in Table S1; see Supporting Information). The reaction was performed in triplicate with the SYBR Green I Master Mix (Roche, Manheim, Germany) on a Light Cycler 480. The amount of amplified product for each gene was compared with that of β-actin using a comparative ΔΔCT method ± SD, and the data are presented as fold change.

- **Immunofluorescence labelling**: For detection and visualization of protein expression in HFs, tyramide signal amplification (TSA) was applied for CRH-R1/2, insulin-like growth factor (IGF)-1, inositol triphosphate receptor (IP3-R), melanocortin receptor 2 (MC-R2), p75 neurotrophin receptor (p75 NTR), and transforming growth factor (TGF)-β2. The standard immunofluorescence procedure was used for ACTH, SP, NGF-tyrosine kinase receptor A (TrkA), and Ki-67. A detailed description of the procedures is provided in Appendix S3 and Table S2 (see Supporting Information).

- **Statistical analysis**: A description of the statistical analyses is provided in Appendix S4 (see Supporting Information).

---

### Neural responses to social evaluative threat in the absence of negative investigator feedback and provoked performance failures [^115zwKqx]. Human Brain Mapping (2020). Low credibility.

- **General protocol**: Subjects were instructed not to (a) ingest food or caffeine 2 hours prior to study participation, (b) exercise on the study day or the evening before, and (c) sleep during the study day. Data collection took place in the evenings (5–9 p.m.). Prior to fMRI, participants rested in a supine position for 15 minutes in a quiet room to ensure comparable baseline conditions across subjects. Arousal indicators were collected offline, including heart rate, blood pressure, and saliva cortisol at five different times: T1 after rest, T2 before fMRI, T3 in between the two fMRI runs, T4 after fMRI, and T5 approximately 20 minutes after task completion. Arousal was also measured online during the two fMRI runs with continuous heart rate and pupil diameter monitoring, as well as self-assessment manikin (SAM) arousal assessments at the end of each trial.

- **Evaluative social stress paradigm**: During fMRI, participants anticipated, prepared, and delivered free speeches on selected topics. The task conditions differed only in the presence or absence of social evaluative threat (SET) during speech production, determined by the type of video clips displayed during the speeches. All other task elements were identical for both conditions.

---

### European consensus guidelines on the management of respiratory distress syndrome: 2022 update [^116uGDo7]. Neonatology (2023). High credibility.

The 2023 ECG-RDS guidelines for the medical management of neonatal respiratory distress syndrome specifically recommend the administration of caffeine, with a loading dose of 20 mg/kg and a maintenance dose of 5–10 mg/kg, to facilitate weaning from mechanical ventilation.

---

### Effect of increased potassium intake on adrenal cortical and cardiovascular responses to angiotensin II: A randomized crossover study [^114BmfEW]. Journal of the American Heart Association (2021). Low credibility.

Increased potassium intake decreases blood pressure (BP) in patients with hypertension. However, it also increases plasma concentrations of the BP‐raising hormone aldosterone. This apparent paradox is not fully understood, but reports dating back to 1935 suggest that potassium acts as a diuretic. In line with this suggestion, newer studies have shown that a single oral load of 100 mmol of potassium chloride and five days on a fixed low potassium run‐in diet, followed by five days on the fixed diet but including a 100 mmol/day potassium chloride supplementation, lead to significant increases in urinary sodium excretion. Additionally, potassium inhibits the sodium chloride cotransporter (a thiazide-like effect) in the distal convoluted tubule of the kidney, leading to increased natriuresis. Further studies of longer duration (≥ 4 weeks) have observed that increased potassium intake also leads to rises in plasma renin concentration and plasma renin activity, which provides some indirect support for a diuretic action of potassium.

Besides its well‐known renal effects, aldosterone is also believed to have vascular effects, acting through mineralocorticoid receptors present in endothelial and vascular smooth muscle cells. However, mineralocorticoid receptor-independent actions are also thought to be involved.

Aldosterone is primarily secreted from the zona glomerulosa in the adrenal cortex. Nonetheless, studies suggest that aldosterone can be synthesized outside the adrenal cortex as well.

---

### How should we interrogate the hypothalamic-pituitary-adrenal axis in patients with suspected hypopituitarism [^111132b8]. BMC Endocrine Disorders (2016). Low credibility.

The choice of test used to interrogate the HPA axis should be individualized for each patient, and the results should be interpreted within the clinical context with an understanding of the potential pitfalls of the test used. If the result is borderline and clinical suspicion is high, an alternative test should be performed. Clinical vigilance is required, and patients should be made aware of the symptoms and signs of adrenal insufficiency so that assessment can be repeated if necessary. Results should be interpreted rationally; those with apparent borderline normal/abnormal results or values suggestive of partial ACTH deficiency could be treated with short courses of stress doses of glucocorticoids during illness only.

---

### New effects of caffeine on corticotropin-releasing hormone (CRH)-induced stress along the intrafollicular classical hypothalamic-pituitary-adrenal (HPA) axis (CRH-R1/2, IP-R, ACTH, MC-R2) and the neurogenic non-HPA axis (substance P, p75and TrkA) in ex vivo human male androgenetic scalp hair follicles [^116NwYPw]. The British Journal of Dermatology (2021). Low credibility.

Hair loss is deeply stressful for affected patients, and perceived stress might aggravate conditions such as male and female pattern androgenetic alopecia (AGA) or diffuse alopecia. Animal models have shown that stress impairs hair growth by catagen induction mediated by substance P (SP), mast cell activation, and nerve growth factor (NGF), as confirmed in human hair follicles (HFs) ex vivo.

Stress can be mediated by oxidative stress or stress hormones, with corticotropin-releasing hormone (CRH) being a primary hormonal stress actor. CRH inhibits growth and induces premature entry into the catagen phase in human scalp HFs ex vivo, which is consistent with the wide CRH expression and signaling in human skin, including direct proinflammatory activities. However, an established human hair stress model and related treatment principle are lacking so far.

HFs are skin appendages that survive and proliferate independently of the skin in vitro, for example, in the human hair organ culture model. They undergo lifelong repeating growth cycles, synthesize, metabolize, and process numerous (neuroendocrine) hormones; thus, they represent an essential part of the skin neuroendocrine system. Additionally, HFs (and skin) express a fully functional peripheral cutaneous equivalent of the central hypothalamic-pituitary-adrenal (HPA) stress axis [CRH → adrenocorticotropic hormone (ACTH) → cortisol], responsive even to ultraviolet B-induced stress. Finally, HFs (and the skin) manage locally occurring stress and therefore can serve excellently as a human ex vivo hair stress model.

---

### Psychotropic medication effects on cortisol: Implications for research and mechanisms of drug action [^113uHKJN]. Schizophrenia Research (2019). Low credibility.

Stress and the hypothalamic-pituitary-adrenal (HPA) axis have been implicated in the etiology of a range of psychiatric disorders; abnormalities in cortisol secretion are well documented in mood, anxiety, and psychotic disorders. There is, however, evidence that psychotropic medications affect HPA function, and are often a confounding factor in research on the relationship between cortisol secretion and psychiatric symptoms and syndromes. Psychotropic effects are particularly problematic in longitudinal research on individuals at clinical high risk (CHR) for serious mental illness because they have the potential to obscure neurobiological mechanisms involved in crossing the threshold from CHR states to clinical disorders.

This paper reviews the research literature on the relation of cortisol secretion with the three major classes of psychotropic medication that are most often prescribed: antipsychotics, antidepressants, and stimulants. The studies included in this review are those that measured both baseline and post-treatment cortisol. Taken together, most studies of antidepressants find that they are associated with a reduction in both basal and post-dexamethasone-CRH (DEX/CRH) cortisol, although some report no change. Similarly, antipsychotics, both typical and atypical, are found to reduce basal and DEX/CRH cortisol levels in most studies. Psychostimulant medications, in contrast, are associated with an increase in basal cortisol levels or no change. Effects of psychotropics on the cortisol awakening response (CAR) are less consistent.

Implications of these effects for clinical research include potential challenges in accurately assessing the neurobiological mechanisms that underlie psychiatric disorders, given the influence of medication on HPA axis function and cortisol levels.

---

### EFNS guideline on the treatment of tension-type headache - report of an EFNS task force [^115aojvX]. European Journal of Neurology (2010). High credibility.

Regarding medical management for tension-type headache, specifically in relation to acute therapy, the EFNS 2010 guidelines recommend offering combination analgesics containing caffeine as second-line therapy for patients with episodic tension-type headaches.

---

### Higher n-3 fatty acids are associated with more intense fenfluramine-induced ACTH and cortisol responses among cocaine-abusing men [^113bCZDM]. Psychiatry Research (2011). Low credibility.

Preclinical studies have shown that diets supplemented with or deficient in n-3 polyunsaturated fatty acids (PUFAs) could influence serotonergic neurotransmission, but information about their effects on the serotonergic function of humans is scant. Therefore, simultaneous assessments of n-3 PUFAs and of the adrenocorticotropic hormone (ACTH) and cortisol responses to challenges with the serotonin (5-HT) probe d, l-fenfluramine (FEN) were performed in 25 cocaine-abusing men and 12 control subjects.

Cocaine abusers were tested 18 days after their admission to a closed ward. ACTH and cortisol were measured in plasma samples collected on two testing days separated by 48 hours following the random administration of 60 mg of FEN or placebo. Fatty acids were measured in the first test day samples. Patients' FEN-induced ACTH rises were significantly and positively correlated with docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). Patients' cortisol rises were positively and significantly correlated with EPA but not with DHA. There were no significant correlations between hormonal responses and pre-hospitalization cocaine use parameters. Control subjects' responses to FEN were not correlated with any PUFA.

In conclusion, higher EPA and DHA levels were associated with a more intense FEN-induced ACTH response, and higher EPA levels were associated with a more intense cortisol response in cocaine-abusing men withdrawn from cocaine but not in control subjects. These findings support and expand existing evidence that EPA and DHA could influence 5-HT function in some human subgroups.

---

### Dsuvia [^115es9Xe]. U.S. Food and Drug Administration (2023). High credibility.

Opioids inhibit the secretion of adrenocorticotropic hormone (ACTH), cortisol, and luteinizing hormone (LH) in humans. They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon [see Adverse Reactions (6.2)].

Use of opioids for an extended period of time may influence the hypothalamic-pituitary-gonadal axis, leading to androgen deficiency that may manifest as low libido, impotence, erectile dysfunction, amenorrhea, or infertility. The causal role of opioids in the clinical syndrome of hypogonadism is unknown because the various medical, physical, lifestyle, and psychological stressors that may influence gonadal hormone levels have not been adequately controlled for in studies conducted at the time of writing [see Adverse Reactions (6.2)].

- **Effects on the immune system**: Opioids have been shown to have a variety of effects on components of the immune system with in vitro and animal models. The clinical significance of these findings is unknown. Overall, the effects of opioids appear to be modestly immunosuppressive.

- **Effects on the respiratory system**: All opioid mu-receptor agonists, including DSUVIA, produce dose-dependent respiratory depression. The risk of respiratory depression is less in patients receiving chronic opioid therapy who develop tolerance to respiratory depression and other opioid effects. Serious or fatal respiratory depression can occur even at recommended doses. Although not observed with DSUVIA in the clinical trial, sufentanil given rapidly by intravenous injection in large doses m

---

### Concomitant medication use can confound interpretation of the combined dexamethasone-corticotropin releasing hormone test in Cushing's syndrome [^115S1GGE]. The Journal of Clinical Endocrinology and Metabolism (2009). Low credibility.

The ability of combined dexamethasone-corticotropin releasing hormone (Dex-CRH) testing to distinguish pseudo-Cushing's syndrome (PCS) from Cushing's syndrome is controversial. One factor potentially impairing diagnostic efficacy is the concomitant use of commonly prescribed medications that may alter dexamethasone metabolism.

- **Objective**: Our objective was to assess the diagnostic accuracy of the Dex-CRH test and evaluate the potential impact of concomitant drugs.

- **Design**: The study was a retrospective one.

- **Participants**: Participants included 101 patients (60 Cushing's disease (CD); 41 PCS) who underwent 112 Dex-CRH tests. Patients were divided into two groups, depending on use of medications potentially interfering with dexamethasone metabolism: 58 tests were classified as No Meds (32 CD; 26 PCS) and 54 as Meds (34 CD; 20 PCS). The latter group was further subdivided into patients taking one medication vs. those taking multiple medications.

- **Main outcome measures**: Diagnostic accuracy of different serum cortisol and ACTH thresholds at baseline and 15 min after CRH injection was assessed.

- **Results**: The specificity of a baseline post-low-dose-dexamethasone-suppressed test cortisol lower than 1.4 microg/dl (38 nmol/liter) was significantly higher in the No Meds vs. the Meds group (P = 0.014). Sensitivity and specificity using a post-CRH cortisol cutoff of 1.4 microg/dl (38 nmol/liter) were 93.1% (95% confidence interval = 88.4–97.8) and 92.3% (95% confidence interval = 87–97.6) in the No Meds group.

---

### Multiple effects of caffeine on simulated high-intensity team-sport performance [^11569vCU]. Medicine and Science in Sports and Exercise (2005). Low credibility.

Caffeine enhances the performance of single bouts of endurance exercise, but its effects on repeated bouts typical of those in high-intensity team sports are unclear. This study aimed to investigate the effects of caffeine in a performance test simulating the physical and skill demands of a rugby union game.

The study employed a double-blind, randomized, crossover design in which nine competitive male rugby players ingested either caffeine (6 mg/kg body mass) or a placebo (dextrose) 70 minutes before performing a rugby test. Each test comprised seven circuits in each of two 40-minute halves with a 10-minute halftime rest. Each circuit included stations for measuring sprint time (two straight-line and three agility sprints), power generation in two consecutive drives, and accuracy for passing balls rapidly. Interstitial fluid samples were obtained transdermally by electrosonophoresis before ingestion of caffeine or placebo, and then before testing, at halftime, and immediately after testing. Samples were analyzed chromatographically for caffeine and epinephrine concentrations.

The results showcased the effects of caffeine on mean performance with (± 90% confidence limits) over all 14 circuits: sprint speeds increased by 0.5% (± 1.7%) to 2.9% (± 1.3%); first-drive power improved by 5.0% (± 2.5%); second-drive power decreased by -1.2% (± 6.8%); and passing accuracy enhanced by 9.6% (± 6.1%). The enhancements were mediated partly through a reduction of fatigue that developed throughout the test and partly by enhanced performance for some measures from the first circuit. Caffeine led to a 51% (± 11%) increase in mean epinephrine concentrations.

---

### Inhibition of parathyroid hormone secretion by caffeine in human parathyroid cells [^113m5Fgk]. The Journal of Clinical Endocrinology and Metabolism (2013). Low credibility.

cAMP is another important second messenger that mediates caffeine function. Caffeine is known to modulate the intracellular cAMP level through inactivation of the G protein-coupled receptors ADORA 1 and ADORA 2A and inhibition of phosphodiesterase. In parathyroid cells, cAMP has been found to have a positive association with PTH secretion. Several compounds, such as the β-adrenergic agonists isoproterenol and epinephrine and forskolin, have been shown to enhance cAMP accumulation and PTH release. In our study, we observed a decrease in cAMP at 50 μcaffeine in parallel with a decrease in PTH secretion. The expected increase in cAMP at a very high concentration of caffeine is most probably a result of inhibition of phosphodiesterase.

Simultaneously, we observed decreased ADORA1 gene expression at 10 and 50 μ, whereas no obvious alterations in ADORA2A expression were recorded. We detected both ADORA 1 and ADORA 2A at the protein level in normal parathyroid and parathyroid adenomas. ADORA 1 showed an equal expression in normal and parathyroid adenomas, whereas ADORA 2A was found to be weak or absent in some parathyroid adenoma samples. Increased or unaltered ADORA1 mRNA expression has been reported in the brain after long-term caffeine treatment. Other studies also found that short-term caffeine treatment reduces adenylyl cyclase activity, whereas chronic caffeine treatment results in increased adenylyl cyclase activity due to adaptation after caffeine intake. The decrease in ADORA1 expression observed in this study may be due to the short-term caffeine incubation.

---

### Nucynta [^112afyRu]. U.S. Food and Drug Administration (2023). High credibility.

Opioids inhibit the secretion of adrenocorticotropic hormone (ACTH), cortisol, and luteinizing hormone (LH) in humans [see Adverse Reactions (6.2)]. They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon.

Use of opioids for an extended period of time may influence the hypothalamic-pituitary-gonadal axis, leading to androgen deficiency that may manifest as low libido, impotence, erectile dysfunction, amenorrhea, or infertility. The causal role of opioids in the clinical syndrome of hypogonadism is unknown because the various medical, physical, lifestyle, and psychological stressors that may influence gonadal hormone levels have not been adequately controlled for in studies conducted [see Adverse Reactions (6.2)].

- **Effects on the immune system**: Opioids have been shown to have a variety of effects on components of the immune system with in vitro and animal models. The clinical significance of these findings is unknown. Overall, the effects of opioids appear to be modestly immunosuppressive.

- **Concentration-efficacy relationships**: The minimum effective analgesic concentration will vary widely among patients, especially among those who have been previously treated with opioid agonists. The minimum effective analgesic concentration of tapentadol for any individual patient may increase over time due to an increase in pain, the development of a new pain syndrome, and/or the development of analgesic tolerance [see Dosage and Administration (2.1, 2.6)].

---

### Metopirone [^112NXGRc]. U.S. Food and Drug Administration (2025). High credibility.

- **Dosage and administration**: The single-dose short test requires 30 mg/kg of Metopirone to be administered at midnight.

- **Important information before conducting Metopirone testing**: Discontinue drugs that affect pituitary or adrenocortical function according to their half-lives to prevent interference with Metopirone testing [see Drug Interactions (7.1)]. Evaluate the adrenal response to exogenous ACTH before employing Metopirone as a test [see Warnings and Precautions (5.1)].

- **Single-dose short test - recommended dose and interpretation**: This test, generally conducted on an outpatient basis, assesses plasma 11-desoxycortisol and/or ACTH levels following a single dose of Metopirone. Patients showing signs of adrenocortical insufficiency should be hospitalized overnight as a precaution (see Warnings and Precaution (5.1)).

	- **Recommended dose**: For adults and pediatric patients, administer a single dose of 30 mg/kg (up to 3 grams of Metopirone) at midnight with milk, yogurt, or a snack. Blood samples for analysis should be taken early the next morning (between 7:30–8:00 a.m.). Consider a prophylactic dose of glucocorticoid for patients at high risk for acute adrenal insufficiency.

	- **Interpretation of 11-desoxycortisol and ACTH levels after Metopirone administration**: Approximately 8 hours post-administration, assess ACTH and 11-desoxycortisol levels. Normal values will vary according to the method used.

---

### The glucocorticoid receptor: Isoforms, functions, and contribution to glucocorticoid sensitivity [^116g6H52]. Endocrine Reviews (2024). Low credibility.

The HPA axis is regulated by negative feedback at multiple levels. Ultrashort feedback loops occur in the hypothalamus (CRH-mediated) and pituitary (ACTH-mediated) through autocrine inhibition. Short feedback loops inhibiting CRH secretion occur in the hypothalamus, either through neural projections from the arcuate nucleus in response to CRH or hormonally by ACTH.

The latter has been demonstrated via in vitro studies, which has been confirmed to occur in vivo in patients with Addison disease or hypopituitarism (who have baseline elevated CRH), but not in normal subjects (in whom it is assumed long feedback from cortisol masks this mechanism). As cortisol is secreted in response to ACTH, it acts via the GR in long feedback loops to inhibit CRH and AVP mRNA transcription in the hypothalamus and POMC transcription and post-translational modification (into ACTH) in the anterior pituitary, thereby limiting exposure to glucocorticoids in response to stress.

This can also occur rapidly (< 20 minutes) through nongenomic, GR-mediated mechanisms, likely acting to prevent pre-formed ACTH release from corticotropes and blocking CRH stimulation, thus inhibiting ongoing pulsatile secretion of ACTH and cortisol. Supraphysiological doses of glucocorticoids can suppress HPA axis function through inducing constant, potent, negative feedback on the hypothalamus and pituitary. This is estimated to occur in 48% to 63% of those receiving long-term treatment, but has also been demonstrated after short or recurring courses of high-dose glucocorticoids.

---

### Sex differences and caffeine impact in adenosine-induced hyperemia [^113zcGsW]. Journal of Nuclear Medicine (2022). Low credibility.

Stress MBF and MFR were observed to fluctuate for the women at different plasma caffeine concentrations. These effects may be caused by the low number of measurements obtained for the plasma caffeine concentrations ranging between 1 and 5 mg/L and, thus, statistical noise. The general reduction in stress MBF for scans obtained after caffeine consumption reported for the male volunteers was in concurrence with previous studies. Test-retest repeatability was tested for the baseline scans for all subjects with plasma caffeine concentrations < 1 mg/L. In this context, test-retest repeatability was found in concordance with previous studies evaluating the short-term variation in rest MBF. The test-retest repeatability measures, therefore, suggest that reductions in the MBF and MFR assessments observed for high plasma caffeine concentrations were introduced by the ingestion of caffeine. This finding is supported by the observed physiologic responses to caffeine ingestion. In concordance with previous studies, women had greater increases in diastolic blood pressure after caffeine administration than men. One explanation for this effect may be that men have a more sensitive baroreflex than women. Further, sex differences in hemodynamic response to caffeine may be related to sex steroid hormone concentrations. When taken together, these studies suggest that men are more responsive to caffeine than women, a hypothesis supported by the findings in this study since caffeine had a greater potency in reducing stress MBF in men than women.

---

### SPL drug information for cosyntropin [^116yHbqB]. U.S. Food and Drug Administration. High credibility.

Labeled indications for cosyntropin (also known as Cortrosyn) include the induction of the adrenocorticotropic hormone stimulation test in adults.

---

### The glucocorticoid receptor: Isoforms, functions, and contribution to glucocorticoid sensitivity [^113nNGEC]. Endocrine Reviews (2024). High credibility.

Following a standardized laboratory-induced psychological stress (Trier Social Stress Test), male subjects exhibit a greater ACTH response than female subjects (except those in the luteal phase) along with greater salivary free cortisol peak during the recovery period. Stress involving a social rejection trigger may induce a greater cortisol response in female subjects; however, this finding could not be replicated. Physical triggers similarly demonstrate sexual dimorphism in HPA axis response with no difference in response to endurance exercise. Female participants generate greater cortisol levels following heat and cold exposure, while males demonstrate a greater salivary cortisol response to noxious stimuli.

Finally, responses to pharmacological manipulation of the HPA axis differ, with female subjects demonstrating a greater response of ACTH and cortisol to naloxone; ACTH (and a more prolonged cortisol peak) to ovine CRH; ACTH and cortisol to combined human CRH and AVP; cortisol following dexamethasone-suppressed CRH; and salivary free cortisol with ACTH 1–24 stimulation (greater in luteal phase). As aging occurs, the responsivity to pharmacological tests of HPA function tends to increase, disproportionately so in females.

The underlying pathophysiological mechanisms of sexual dimorphism in HPA axis function are reviewed in depth elsewhere. Where relevant data is available, sex differences will be covered in subsequent sections of this paper.

---

### Acthrel [^1172DsTE]. U.S. Food and Drug Administration (2021). High credibility.

The interpretation of the ACTH and cortisol responses following ACTHREL® administration requires knowledge of the clinical status of the individual patient, understanding of hypothalamic-pituitary-adrenal physiology, and familiarity with the normal hormonal ranges and the standards used by the laboratory that performs the ACTH and cortisol assays.

- **Cushing's disease**: The results of the challenge with corticorelin injection have been reported in approximately 300 patients with Cushing's disease. Although the ACTH and cortisol responses were variable, a hyper-response to corticorelin was seen in a majority of patients, despite high basal cortisol levels. This response pattern indicates an impairment of the negative feedback of cortisol on the pituitary. Patients with pituitary-dependent Cushing's disease tested with corticorelin do not show the negative correlation between basal and stimulated levels of ACTH and cortisol that is found in normal subjects. A positive correlation between basal ACTH levels and maximum ACTH increments after corticorelin administration has been found in Cushing's disease patients.

- **Ectopic ACTH secretion**: Patients with Cushing's syndrome due to ectopic ACTH secretion (N = 32) were found to have very high basal levels of ACTH and cortisol, which were not further stimulated by corticorelin. However, there have been rare instances of patients with ectopic sources of ACTH that have responded to the corticorelin test.

- **Cushing's disease ACTH responses**:
	- **Mean of 181 patients**:
		- **Basal ACTH**: 63 ± 72 pg/mL (mean ± SD)
		- **Peak ACTH**: 18